Astellas Pharma (South Korea)

Astellas Pharma (South Korea)

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Astellas Pharma (South Korea), South Korea, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

75%


Total
Publications

57


Total Open
Publications

43


Total
Citations

468


Open Access
Percentage

75%


Total
Publications

57


Total Open
Publications

43


Total
Citations

468

Wikipedia

Website

download

Breakdown

33% 40% 2% 25%

Publisher Open

33%

Both

40%

Other Platform Open

2%

Closed

25%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

012345678Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

60%OA Journal

OA Journal 60%

25

Hybrid 26%

11

No Guarantees 14%

6

Other Platform Open

Domain 54%

13

Institution 29%

7

Other Internet 29%

7

Public 21%

5

Preprint 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
13
Europe PMC
Domain
7
Semantic Scholar
Public
5
Yonsei University Medical Library - YUHSpace
Institution
3
Unknown Repository
Other Internet
3
OpenEdition - OpenEdition
Other Internet
3
Universidad de la Rioja - Dialnet
Institution
2
University of Oxford - Oxford Academic Notes & Queries
Institution
1
Universidad de Alicante - RUA, Repositorio Institucional de la Universidad de Alicante
Institution
1
Red Federada de Repositorios Institucionales de Publicaciones Científicas - LA Referencia
Institution
1
1 / 2

Data updated 7 April 2025

Share

Share

Share